

**DENV1**

**GTS1SP**

	TRBV	CDR3	TRBJ	Freq (%)
1-1166	12-3/4	CASSLGSYEQY	2-7	18.31
	11-2	CASSLVGGTPSYNEQF	2-1	15.49
	11-2	CASSLFAGGPDTQY	2-3	11.27
	12-3/4	CASSWGAAEAF	1-1	11.27
	12-3/4	CASSLGLPTLY	2-3	9.86
	11-2	CASSLVIPTGWRDNEQF	2-1	5.63
	7-3	CASSLNSGSAGELF	2-2	5.63
	5-5	CASSRHGSGVDQPQH	1-5	4.23
	11-2	CASSLAVGGYEQY	2-7	2.82
	12-3/4	CASSPGTLYGYT	1-2	2.82
	12-3/4	CASSLGNNEQF	2-1	2.82
	11-2	CASSLVFAGGTSTDTQY	2-3	1.41
	11-2	CASSLVFAGGISTDTQY	2-3	1.41
	5-5	CASSRHGPGVDQPQH	1-5	1.41
	12-3/4	CASSFFPGSGETQY	2-5	1.41
	11-2	CASSTRGGGYEQY	2-7	1.41
	12-3/4	CASSWGSDTQY	2-3	1.41
	12-3/4	CASSLGAGELF	2-2	1.41

	TRBV	CDR3	TRBJ	Freq (%)
1-2528	12-3/4	CASSPGTAEAF	1-1	28.95
	12-3/4	CASSWGSYEQF	2-1	23.68
	12-3/4	CASSLGGKYSF	2-1	18.42
	12-3/4	CASSPGTDEAF	1-1	15.79
	7-8	CASSLTAGTQETQY	2-5	11.84
	12-3/4	CASSSGSYEQF	2-1	1.32

	TRBV	CDR3	TRBJ	Freq (%)
2-0600	11-2	CASSLAGGAYEQY	2-7	38.20
	12-3/4	CASSIGVETQY	2-5	28.09
	12-3/4	CASSPGTLHGTY	1-2	19.10
	11-2	CASSQGGGNYEQY	2-7	13.48
	12-3/4	CASSPGTGELF	2-2	1.12

	TRBV	CDR3	TRBJ	Freq (%)
2-2781	12-3/4	CASNLTGETQY	2-5	11.94
	11-2	CASSLGPDNEQF	2-1	10.45
	12-3/4	CASSPGVEKLF	1-4	7.46
	12-3/4	CASSLVPEAF	1-1	7.46
	11-2	CASPTLWGDQETQY	2-5	5.97
	11-2	CASSLYQGVEQF	2-1	5.97
	12-3/4	CASSSGSYEQY	2-7	5.97
	11-2	CASSLGSAAEAF	1-1	5.97
	11-2	CASSLAVRSSYNEQF	2-1	4.48
	12-5	CASSPGQESYEQY	2-7	4.48
	12-3/4	CASSPGANGYT	1-2	4.48
	7-3	CASSLRLRLAGALRNVEQY	2-7	2.99
	11-2	CASSLGGGSRVMGYEQF	2-1	2.99
	11-2	CASSLGGGAYEQY	2-7	2.99
	27	CASSPGEATNTGELF	2-2	1.49
	11-2	CASSLGAGTADFGYT	1-2	1.49
	12-3/4	CASSIAGGTDQY	2-3	1.49
	12-3/4	CASSFTGSSYEQY	2-7	1.49
	11-2	CASNLTGGEGDQY	2-5	1.49
	11-2	CASSLGTGATEAF	1-1	1.49
6-1	CASSVYTGTEAF	1-1	1.49	
12-3/4	CASSLGTENTY	1-3	1.49	
12-3/4	CASSLGGAAEAF	1-1	1.49	
12-3/4	CASSPGAGELF	2-2	1.49	
12-3/4	CASNPGAGELF	2-2	1.49	

	TRBV	CDR3	TRBJ	Freq (%)
1-2368	12-3/4	CASPTGLWNTAEAF	1-1	43.55
	12-3/4	CASSPGTEHGYT	1-2	19.35
	12-3/4	CASSLGSYEQY	2-7	14.52
	3-1	CASSGTSFREQF	2-1	6.45
	12-3/4	CASSPGGARAF	1-1	6.45
	12-3/4	CASSRGSSELF	2-2	3.23
	12-3/4	CASSPGSHEAF	1-1	3.23
	20-1	CSATMGGTDQPQH	1-5	1.61
	12-3/4	CASNPGSYEQY	2-7	1.61

**DENV1/DENV2**

**GTS1SP**

	TRBV	CDR3	TRBJ	Freq (%)
2-1452	9	CASSRGSSETQY	2-5	45.12
	11-2	CASSFGGGAETQY	2-5	41.46
	11-2	CASSLGPEDTQY	2-3	13.41

**Supplementary Figure 1** TRBV and TRBJ usage, CDR3 $\beta$  amino acid sequence, and clonotype frequency are shown for CD3<sup>+</sup>CD8<sup>+</sup>CD14<sup>-</sup>CD19<sup>-</sup> HLA-A\*11:01-GTS1 tetramer<sup>+</sup> populations isolated from patients with primary DENV1 infection or sequential DENV1/DENV2 infections. Recurrent clonotypes are highlighted in color. SP, single positive.